|
(Alliance News) - AstraZeneca PLC and Merck & Co Inc on Monday reported positive trial results for Lynparza in combination with abiraterone in patients with prostate cancer.
Results from the PROpel phase three trial showed Lynparza in combination with abiraterone reduced the risk of disease progression or death by 34% in patients with metastatic castration-resistant prostate cancer versus just abiraterone alone.
Results also showed a favourable trend towards improved overall survival, however the difference did not reach statistical significance at the time of the data cut-off. The trial will continue to assess overall survival as a key secondary endpoint.
"The PROpel results are impressive because active comparator trials set a high bar and, in this trial, Lynparza plus abiraterone showed a significant clinical improvement when compared to an active standard of care in patients with metastatic castration-resistant prostate cancer, regardless of whether they have an HRR gene mutation," said Susan Galbraith, executive vice president, Oncology R&D, at AstraZeneca.
By Lucy Heming; lucyheming@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
